Clinical Need

Soft tissue deformities and volume/contour deformities from craniofacial trauma, congenital anomalies, and cancer treatment are difficult to correct. Current standard of care includes injectable fillers, implants, and soft tissue flap procedures, which have limitations and often involve operations with significant risk. As such, autologous fat transfer is being explored as a lower risk alternative. However, as optimal results with fat transfer often require at least two treatments, there is a need for an on-site preservation of harvested tissue for subsequent procedures to minimize donor site morbidity and encourage fast recovery.

Solution

A team of researchers at the University of Pittsburgh led by Dr. Peter Rubin has previously validated the use of autologous fat transfer as a minimally invasive therapy for the restoration of craniofacial form. In order to facilitate fat transfer with minimal donor site morbidity, the team has developed a novel device to cryopreserve adipose for storage at the treatment facility, which can directly be used for the subsequent fat transfer(s).

Competitive Advantage

With the on-site cryopreservation and storage of the fat tissue, the device is envisioned to reduce patient and clinician burden for tissue harvest. The utilization of the device obviates the need for repeat tissue grafting procedures, and is anticipated to lead to reduction in treatment costs as the fat transfer injections may be performed outside of an operating room in a less acute setting.

How the ITP Program Supports this Project

The work supported by the ITP program is focused on the generation of a prototype cryopreservation/storage device that can be used for clinical trials. Toward that end, project plans include prototype development and validation, as well as the development of a regulatory strategy and commercialization plan.

Clinical Translation Pathway

Intellectual Property:
Provisional patent application filed, Sept 2017

Commercialization Strategy:
In development with the MPWRM Commercialization/Market Needs Core

Regulatory Pathway:
In development with the MPWRM Regulatory Core

Product Launch Strategy:
In development with the MPWRM Commercialization/Market Needs Core

Contact Information:
Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center www.doctr.com

Mutsumi Yoshida, PhD
Managing Director, U-M site
yoshidam@umich.edu
(734) 764-4622

J. Peter Rubin, MD, FACS
University of Pittsburgh

“The ability to easily and inexpensively store tissue onsite will result in significant decrease in patient discomfort and risk, as well as significant decrease in surgeon time spent on the repeat procedure.”

plasticsurgery.pitt.edu/research/research-labs/adipose-stem-cell-center-ascc/